Medical Advocates
Ethics and Infectious Diseases
  Ethical Challenges
Screening/Testing
 Refusal of Care/Services
Detention
Patient Exploitation
Compulsory Treatment
Decision-Making
Reproduction
Transplants
End-of-Life Care
Enteral Nutrition
Professional Associations
National Challenges         Sterilization
Bioterrorism                     Prison Challenges
 HIV Exceptionalism           Conflicts of Interest
Pharmaceutical Industry   Pregnancy
HIV Prevention   
Stigma
 Physician Reimbursement 
Ethics and Disease Challenges and Duties
 HIV Cure
 Ebola Virus Disease
 Executions






 
Ethics Main Page Main New and Noteworthy Home Page

Medical Advocates
Tenofovir Disoproxil Fumarate (Viread)
   
Conference Citations

XX International AIDS Conference
7th IAS Conference on HIV Pathogenesis, Treatment and Prevention
XIX International AIDS Conference
6th IAS Conference
11th Int Workshop on Clin Pharm of HIV
5th IAS Conference
 Archives

ARV Drugs Main Page Main New/Newsworthy  Home Page      
Last Update:  December 06, 2014
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
XX International AIDS Conference
 
7th IAS Conference on HIV Pathogenesis, Treatment and Prevention
 
  • POSTER
         HIV-associated risk behaviour among injecting drug users participating in an HIV pre-exposure prophylaxis trial in Bangkok, Thailand
    S. Vanichseni, M. Martin, P. Suntharasamai, et al
    Poster         Abstract
  • POSTER
         Tenofovir plasma concentrations related with creatinine clearance changes particularly in association with LPV/r in first-line regimen of African patients in Cameroon and Senegal: ANRS 12115 DAYANA sub-study
    G. Peytavin, S. Koulla-Shiro2, P. Lê Minh, et al
    Poster          Abstract
  • A WEEK-IN-REVIEW FEATURED REPOR
    POSTER
         Factors influencing plasma tenofovir concentrations in HIV adults: effect of low body weight, chronic hepatitis C and proximal tubular dysfunction
    N. Thammajaruk, J. Sophonphan, R.A. Ramautarsing, et al
    Poster          -Abstract
  • POSTER
         Predictors of renal insufficiency in patients randomized to second-line lopinavir/ritonavir monotherapy vs. tenofovir/lamivudine/lopinavir/ritonavir
    J. Sophonphan, P. Chetchotisakd, W. Munsakul, et al
     Poster         Abstract
  • POSTER
     Impact of tenofovir (TDF)-containing antiretroviral treatment (ART) modifications to other anti-hepatitis B virus (HBV) regimens in patients co-infected with HIV-HBV
    A. Boyd, J. Gozlan, S. Maylin, et al
    Poster          Abstract
  • The Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial in Thailand: participant adherence and study results
         K. Choopanya, S. Vanichseni, P. Suntharasama1m, et al
    Abstract
  • Predictors of daily tenofovir exposure in Thai subjects taking protease inhibitor-based combination antiretroviral therapy
     S.J. Kerr, N. Thammajaruk, A. Colbers, et al
    Abstract
  • Characterization of a new use for acyclovir and tenofovir using human cervico-vaginal tissue ex vivo
     C. Vanpouile, A. Introini, A. Lisco,  et al
  • Comparison of adherence with pre-exposure prophylaxis among HIV-1-negative clinical trial participants in serodiscordant relationships in Kisumu before and after release of the trial results
     B. Wamuti, J. Odoyo, B. Rono, et al
    Abstract
  • Tenofovir nephrotoxicity in resource-limited setting of western India: higher rate of renal function decline, acute kidney injury and progression to chronic kidney disease compared to western data
     A. Dravid, A. Sadre, S. Dhande,et al
    Abstract
  • Pregnancy incidence and birth outcomes among African women in a clinical trial of pre-exposure prophylaxis: the Partners PrEP Study
     N. Mugo, T. Hong, C. Celum, et al
    Abstract
  • Decline in serum 25-OH vitamin D levels in HIV-hepatitis B virus (HBV) co-infected patients with after long term antiretroviral therapy
     T. Apornpong, R.A. Ramautarsing, S. Ubolyam,et al
         Abstract
  • Transient or low-level replication is common in HIV-HBV co-infected patients treated with long-term tenofovir
         A. Boyd, P. Miailhes, C. Lascoux-Combe, et al
     Abstract
  • Modelling HIV PrEP in humanized mice: pharmacokinetic studies on antiretroviral drugs raltegravir, tenofovir and maraviroc
    R. Akkina, M. Veselinovic C.P. Neff,et al
     Abstract
XIX International AIDS Conference
 
  • POSTER
     Tenofovir associated proximal renal tubular dysfunction in HIV-positive children and adolescents
    A. Camacho-Gonzalez, L. Greenbaum, R. Chakraborty, et al
    Poster     Abstract
  • POSTER
         Prevalence and factors associated with renal dysfunction in HIV positive and negative adults at the University Teaching Hospital, in Lusaka
    J. Banda, A. Mweemba, S. Siziya, et al
     Poster     Abstract
  • POSTER
     Tenofovir-associated kidney function decline with a PI-based versus NNRTI-based regimen
    A. Abraham, B. Lau, M. Estrella, et al
     Poster     Abstract
  • POSTER
         Lessons from the rapid response of Namibia’s supply chain when antiretroviral treatment guidelines changed to
    tenofovir-based first-line regimen
    J. Lates, B. Ongeri, A. Wolde,et al
         Poster     Abstract
  • POSTER
         Scaling-up of triggered viral load in rural Zimbabwe: implications for phasing out of D4T
    S. Van Den Broucke, S. Simons, K. Kranzer, et al
     Poster   Abstract
  • POSTER
     Participant adherence in the Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial in Bangkok
    M. Martin1,, S. Vanichseni, P. Suntharasamai, et al
     Poster        Abstract
  • POSTER
         Morbidity and mortality of injecting drug users participating in the Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial in Thailand
    S. Vanichseni , M. Martin, P. Suntharasamai, et     al
     Poster        Abstract
  • Absence of clinically relevant drug interaction between delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) and tenofovir or lopinavir/ritonavir in healthy subjects
     A. Paccaly, C. Petersen , S. Patil, et al
    Abstract
  • Tenofovir disoproxil fumarate (TDF) pharmacokinetics (PK) with daily dosing in the first week of life (HPTN 057)
    K. Nielsen-Saines, M. Mirochnick, N. Kumwenda, et al
    Abstract
  • Tenofovir plasma pharmacokinetics in AIDS clinical trials group study A5202
         C. Venuto,, Q. Ma, E. Daat. et al
    Abstract
  • Changing patterns of NRTI and PI resistance mutations between 2006 and 2011 in >1,200 ART-experienced South African patients:
    association with the introduction of tenofovir (TDF) and abacavir (ABC) and with the cumulative effects of LPV/r therapy
    G. van Zyl, M. Claassen, S. Engelbrecht, et al
    Abstract